non-small cell lung cancer
Conditions
Interventions
Case series:No
Sponsors
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient is in line with the indications for the use of almetinib before taking the drug; 2. Patients knowingly and voluntarily donate tissue specimens; 3. Need to receive almetinib monotherapy (no other treatment during the period, including radiotherapy/chemotherapy), stable disease prolonged (> 3 months) or partial response to treatment; 4. Clear acquired resistance after treatment (acquired resistance is defined by Jackman's criteria); 5. There are tumor samples before the use of almetinib (if there is no sample, the previous test results can be considered) and after the progression.
Exclusion criteria
Exclusion criteria: 1. The quality of tissue samples does not meet the sequencing standards; 2. Specimens before and after treatment were reviewed and identified as tumor content <50% by pathologist; 3. Previous use of osimertinib followed by sequential use of almetinib.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene and tumor tissue transformation results before and after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progress Free Survival; | — |
Countries
China
Contacts
Public ContactZhang Yu
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Outcome results
None listed